by Michelle Taylor
Available cleanroom space has not kept up with the pace of growth in the pharmaceutical industry, and as a result is slowing time-to-clinic and holding back innovations of new therapies and products. When it comes to cleanrooms, pharmaceutical manufacturers are faced with a dilemma: should they build their own facility, spending years and millions of dollars on validation, or should they outsource to a contract manufacturing organization, standing by on a waitlist that can be up to 18 months or longer? In an industry that needs to “fail fast” to survive, that waitlist can feel insurmountable. Then again, so can spending millions in capital.
A third option that is gaining momentum—especially in the face of the COVID-19 pandemic—is leased cleanroom space. The ability to lease fully equipped laboratory space in a timely manner enables pharmaceutical manufacturers to scale-up without the need for major capital expenses.
In this Ask the Scientist, Vanessa Wiley, associate director of operations at Azzur Cleanrooms on Demand, explains the allure of leased cleanroom space, and how it can help pharmaceutical manufacturers speed innovations.
Read more on Labcompare.